- Allergens for Sublingual Immune Therapy
- Tree Pollen
- Grass- / Cereal- / Herbal Pollen
- House Dust Mites
Allergens for Sublingual Immune Therapy
Allergens for Sublingual Immune Therapy
Therapy allergens are used for Allergen immunotherapy (AIT) in order to restore tolerance to the respective allergen.
In the case of the sublingual immune therapy (also called sublingual hyposensitisation) the allergen extract is placed under the tongue several times a day and swallowed over a longer period of time (as al rule for several years).
Therapy allergens for the sublingual immune therapy are available for the following allergen classes:
- Tree Pollen
- Grass-, Cereal and Herbal Pollen
- House Dust Mites and Storage Mites
Updated: 01.04.2021
Tree Pollen
Tree Pollen
Approved Allergens for Sublingual Immune Therapy against Tree Pollen
Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
---|---|---|---|---|
ITULAZAX |
ALK-Abelló Arzneimittel GmbH |
PEI.H.11987.01.1 | 29.07.2019 | |
ITULAZAX |
kohlpharma GmbH |
PEI.H.12043.01.1 | 19.05.2020 | |
ITULAZAX |
Orifarm GmbH |
PEI.H.12045.01.1 | 24.08.2020 | |
ITULAZAX |
AxiCorp Pharma GmbH |
PEI.H.12070.01.1 | 23.12.2020 | |
ITULAZAX |
EurimPharm Arzneimittel GmbH |
PEI.H.12073.01.1 | 10.12.2020 | |
Staloral Birke 10 IR/ml und 300 IR/ml |
Stallergenes GmbH |
PEI.H.03013.05.1 | 27.04.2005 | |
Staloral Birke 300 IR/ml |
Stallergenes GmbH |
PEI.H.03013.03.1 | 10.08.2004 | |
Staloral Birke/Erle/Hasel 10 IR/ml |
Stallergenes GmbH |
PEI.H.03012.01.1 | 10.08.2004 | |
Staloral Birke/Erle/Hasel 300 IR/ml |
Stallergenes GmbH |
PEI.H.03012.03.1 | 10.08.2004 | |
SUBLIVAC Bäume |
HAL Allergie GmbH |
PEI.H.07974.02.1 | 02.08.2018 | |
SUBLIVAC Birke |
HAL Allergie GmbH |
PEI.H.07972.02.1 | 02.08.2018 |
Hints
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 479 in BAnz AT 01.04.2021 B11.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 01.04.2021
Grass- / Cereal- / Herbal Pollen
Grass- / Cereal- / Herbal Pollen
Approved Allergens for Sublingual Immune Therapy against Grass-, Cereal- and Herbal Pollen
Search results 1 to 25 from a total of 32
Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
---|---|---|---|---|
GRAZAX |
kohlpharma GmbH |
PEI.H.11647.01.1 | 22.07.2013 | |
Grazax |
Orifarm GmbH |
PEI.H.11617.01.1 | 20.03.2014 | |
GRAZAX |
Abacus Medicine A/S |
PEI.H.11865.01.1 | 04.04.2017 | |
Grazax |
A.C.A Müller ADAG Pharma AG |
PEI.H.11886.01.1 | 09.12.2016 | |
Grazax |
ALK-Abelló Arzneimittel GmbH |
PEI.H.03489.01.1 | 20.10.2006 | |
GRAZAX |
CC-Pharma GmbH |
PEI.H.11730.01.1 | 16.01.2015 | |
Grazax |
EMRA-MED Arzneimittel GmbH |
PEI.H.11855.01.1 | 13.06.2016 | |
Grazax 75.000 SQ-T |
EurimPharm Arzneimittel GmbH |
PEI.H.11712.01.1 | 28.07.2014 | |
Grazax 75.000 SQ-T |
AxiCorp Pharma GmbH |
PEI.H.11700.01.1 | 04.12.2014 | |
GRAZAX 75000 SQ-T Lyophilisat zum Einnehmen |
Medicopharm AG |
PEI.H.11889.01.1 | 09.12.2016 | |
Grazax Lyo Tablette |
Pharma Gerke GmbH |
PEI.H.11632.01.1 | 22.07.2013 | |
Oralair 100 IR & 300 IR |
EMRA-MED Arzneimittel GmbH |
PEI.H.11812.02.1 | 24.04.2018 | |
Oralair 100 IR & 300 IR |
Stallergènes S.A. |
PEI.H.03450.01.1 | 24.06.2008 | |
Oralair 100 IR & 300 IR |
2Care4 ApS, Dänemark |
PEI.H.12027.01.1 | 07.08.2020 | |
Oralair 100 IR & 300 IR |
EurimPharm Arzneimittel GmbH |
PEI.H.11797.01.1 | 17.09.2015 | |
Oralair 100 IR & 300 IR |
European Pharma B.V., Niederlande |
PEI.H.11776.01.1 | 06.07.2015 | |
Oralair 100 IR & 300 IR |
Medicopharm AG |
PEI.H.11868.01.1 | 13.10.2016 | |
Oralair 100 IR & 300 IR |
Orifarm GmbH |
PEI.H.11822.01.1 | 06.05.2016 | |
Oralair 100 IR + 300 IR |
kohlpharma GmbH |
PEI.H.11735.01.1 | 22.06.2015 | |
Oralair 300 IR |
European Pharma B.V., Niederlande |
PEI.H.11776.02.1 | 12.12.2016 | |
Oralair 300 IR |
A.C.A Müller ADAG Pharma AG |
PEI.H.11898.01.1 | 05.12.2016 | |
Oralair 300 IR |
EurimPharm Arzneimittel GmbH |
PEI.H.11797.02.1 | 17.09.2015 | |
Oralair 300 IR |
2Care4 ApS, Dänemark |
PEI.H.12027.02.1 | 07.08.2020 | |
ORALAIR 300 IR |
Abacus Medicine A/S |
PEI.H.11943.01.1 | 16.01.2019 | |
Oralair 300 IR |
AxiCorp Pharma GmbH |
PEI.H.11897.01.1 | 05.12.2016 |
Hints
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 479 in BAnz AT 01.04.2021 B11.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 01.04.2021
House Dust Mites
House Dust Mites
Approved Allergens for Sublingual Immune Therapy against House Dust Mites
Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
---|---|---|---|---|
ACARIZAX 12 SQ-HDM |
ALK-Abelló, DK-Horsholm |
PEI.H.11754.01.1 | 08.10.2015 | |
ACARIZAX 12 SQ-HDM |
EurimPharm Arzneimittel GmbH |
PEI.H.12004.01.1 | 04.07.2019 | |
ACARIZAX 12 SQ-HDM |
kohlpharma GmbH |
PEI.H.12042.01.1 | 04.08.2020 | |
Acarizax 12 SQ-HDM |
Orifarm GmbH |
PEI.H.12049.01.1 | 10.12.2020 | |
AITARO 12 SQ-HDM |
ALK-Abelló, DK-Horsholm |
PEI.H.11820.01.1 | 29.12.2015 | |
AMITEND 12 SQ-HDM Lyophilisat |
ALK-Abelló, DK-Horsholm |
PEI.H.11821.01.1 | 29.12.2015 |
Hints
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 479 in BAnz AT 01.04.2021 B11.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 01.04.2021